

# Progress in Understanding and Treating SCN2A-Mediat

Trends in Neurosciences

41, 442-456

DOI: [10.1016/j.tins.2018.03.011](https://doi.org/10.1016/j.tins.2018.03.011)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Case of Neonatal Epileptic Encephalopathy due to SCN2A Mutation Responsive to a Ketogenic Diet. <i>Journal of Pediatric Epilepsy</i> , 2018, 07, 148-151.	0.1	3
2	Lost in Translation: Traversing the Complex Path from Genomics to Therapeutics in Autism Spectrum Disorder. <i>Neuron</i> , 2018, 100, 406-423.	3.8	98
3	Predicting Structural Details of the Sodium Channel Pore Basing on Animal Toxin Studies. <i>Frontiers in Pharmacology</i> , 2018, 9, 880.	1.6	20
4	The state of research on the genetics of autism spectrum disorder: methodological, clinical and conceptual progress. <i>Current Opinion in Psychology</i> , 2019, 27, 1-5.	2.5	27
5	Genetic Landscape of Rett Syndrome Spectrum: Improvements and Challenges. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3925.	1.8	32
6	Scn2a Haploinsufficiency in Mice Suppresses Hippocampal Neuronal Excitability, Excitatory Synaptic Drive, and Long-Term Potentiation, and Spatial Learning and Memory. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 145.	1.4	39
7	The Autism-Associated Gene Scn2a Contributes to Dendritic Excitability and Synaptic Function in the Prefrontal Cortex. <i>Neuron</i> , 2019, 103, 673-685.e5.	3.8	148
8	Generation of an induced pluripotent stem cell line from a patient with autism spectrum disorder and SCN2A haploinsufficiency. <i>Stem Cell Research</i> , 2019, 39, 101488.	0.3	4
9	Histone demethylase KDM5C is a SAHA-sensitive central hub at the crossroads of transcriptional axes involved in multiple neurodevelopmental disorders. <i>Human Molecular Genetics</i> , 2019, 28, 4089-4102.	1.4	18
10	Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na <sup>v</sup> 1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9618-9641.	2.9	21
11	A framework for the investigation of rare genetic disorders in neuropsychiatry. <i>Nature Medicine</i> , 2019, 25, 1477-1487.	15.2	90
12	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies. <i>Diabetes</i> , 2019, 68, 1649-1662.	0.3	22
13	Autism and developmental disability caused by <i>KCNQ3</i> gain-of-function variants. <i>Annals of Neurology</i> , 2019, 86, 181-192.	2.8	73
14	Calcium Channel Dysfunction in Epilepsy: Gain of <i>CACNA1E</i> . <i>Epilepsy Currents</i> , 2019, 19, 199-201.	0.4	13
15	Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform Na <sup>v</sup> 1.7. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8695-8710.	2.9	55
16	Impaired cortico-striatal excitatory transmission triggers epilepsy. <i>Nature Communications</i> , 2019, 10, 1917.	5.8	68
17	Genetic mechanisms of regression in autism spectrum disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 102, 208-220.	2.9	26
18	The landscape of early infantile epileptic encephalopathy in a consanguineous population. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2019, 69, 154-172.	0.9	34

#	ARTICLE	IF	CITATIONS
19	The most recurrent monogenic disorders that overlap with the phenotype of Rett syndrome. <i>European Journal of Paediatric Neurology</i> , 2019, 23, 609-620.	0.7	27
20	Identifying mutations in epilepsy genes: Impact on treatment selection. <i>Epilepsy Research</i> , 2019, 152, 18-30.	0.8	93
21	Further corroboration of distinct functional features in SCN2A variants causing intellectual disability or epileptic phenotypes. <i>Molecular Medicine</i> , 2019, 25, 6.	1.9	42
22	Clinical and genetic spectrum of SCN2A-associated episodic ataxia. <i>European Journal of Paediatric Neurology</i> , 2019, 23, 438-447.	0.7	43
23	Research Domain Criteria: Strengths, Weaknesses, and Potential Alternatives for Future Psychiatric Research. <i>Molecular Neuropsychiatry</i> , 2019, 5, 218-236.	3.0	42
24	Understanding the schizophrenia phenotype in the first patient with the full SCN2A phenotypic spectrum. <i>Psychiatric Genetics</i> , 2019, 29, 91-94.	0.6	11
25	<i>SCN2A</i> channelopathies: Mechanisms and models. <i>Epilepsia</i> , 2019, 60, S68-S76.	2.6	24
26	Phenotypic spectrum and genetics of <i>SCN2A</i>-related disorders, treatment options, and outcomes in epilepsy and beyond. <i>Epilepsia</i> , 2019, 60, S59-S67.	2.6	49
27	Regulatory genes and pathways disrupted in autism spectrum disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 57-64.	2.5	29
28	Use of a personalized phenytoin dosing approach to manage difficult to control seizures in an infant with a SCN2A mutation. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 737-739.	0.8	5
29	Sodium Channels and Pain. , 0, , 233-262.		0
30	Clinical Phenotypes of Carriers of Mutations in CHD8 or Its Conserved Target Genes. <i>Biological Psychiatry</i> , 2020, 87, 123-131.	0.7	22
31	Differential excitatory vs inhibitory SCN expression at single cell level regulates brain sodium channel function in neurodevelopmental disorders. <i>European Journal of Paediatric Neurology</i> , 2020, 24, 129-133.	0.7	18
32	The phenotypic spectrum of SCN2A-related epilepsy. <i>European Journal of Paediatric Neurology</i> , 2020, 24, 117-122.	0.7	68
33	Time to move beyond genetics towards biomedical data-driven translational genomic research in severe paediatric epilepsies. <i>European Journal of Paediatric Neurology</i> , 2020, 24, 35-39.	0.7	2
34	Venom Peptides with Dual Modulatory Activity on the Voltage-Gated Sodium Channel Na <sub>v</sub> 1.1 Provide Novel Leads for Development of Antiepileptic Drugs. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 119-134.	2.5	14
35	Dysfunction of the corticostriatal pathway in autism spectrum disorders. <i>Journal of Neuroscience Research</i> , 2020, 98, 2130-2147.	1.3	58
36	Impact of predictive, preventive and precision medicine strategies in epilepsy. <i>Nature Reviews Neurology</i> , 2020, 16, 674-688.	4.9	59

#	ARTICLE	IF	CITATIONS
37	A mini-review: Bridging the gap between autism spectrum disorder and pain comorbidities. <i>Canadian Journal of Pain</i> , 2020, 4, 37-44.	0.6	3
38	Measurement of genetic diseases as a cause of mortality in infants receiving whole genome sequencing. <i>Npj Genomic Medicine</i> , 2020, 5, 49.	1.7	29
39	Epilepsy-Related Voltage-Gated Sodium Channelopathies: A Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 1276.	1.6	76
40	Functional and pharmacological evaluation of a novel <i>SCN2A</i> variant linked to early-onset epilepsy. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1488-1501.	1.7	13
41	Bidirectional Modulation of the Voltage-Gated Sodium (Nav1.6) Channel by Rationally Designed Peptidomimetics. <i>Molecules</i> , 2020, 25, 3365.	1.7	8
42	Predicting functional effects of missense variants in voltage-gated sodium and calcium channels. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	84
43	Comprehensive characterization of amino acid positions in protein structures reveals molecular effect of missense variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28201-28211.	3.3	68
44	Developmental Predictors of Cognitive and Adaptive Outcomes in Genetic Subtypes of Autism Spectrum Disorder. <i>Autism Research</i> , 2020, 13, 1659-1669.	2.1	13
45	Transcriptional subtyping explains phenotypic variability in genetic subtypes of autism spectrum disorder. <i>Development and Psychopathology</i> , 2020, 32, 1353-1361.	1.4	3
46	Transcriptome analysis of neural progenitor cells derived from Lowe syndrome induced pluripotent stem cells: identification of candidate genes for the neurodevelopmental and eye manifestations. <i>Journal of Neurodevelopmental Disorders</i> , 2020, 12, 14.	1.5	12
47	Ion Channels Involvement in Neurodevelopmental Disorders. <i>Neuroscience</i> , 2020, 440, 337-359.	1.1	21
48	Electrophysiological features: The next precise step for <i>SCN2A</i> developmental epileptic encephalopathy. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2020, 8, e1250.	0.6	8
49	Muscle and brain sodium channelopathies: genetic causes, clinical phenotypes, and management approaches. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 536-547.	2.7	13
50	Sodium channel epilepsies and neurodevelopmental disorders: from disease mechanisms to clinical application. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 784-792.	1.1	23
51	Neonatal seizures: When semiology points to etiology. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 80, 161-165.	0.9	12
52	Development and validation of a novel 15â€CpG-based signature for predicting prognosis in triple-negative breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9378-9387.	1.6	7
53	Biological concepts in human sodium channel epilepsies and their relevance in clinical practice. <i>Epilepsia</i> , 2020, 61, 387-399.	2.6	65
54	Advances in genetic testing and optimization of clinical management in children and adults with epilepsy. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 251-269.	1.4	45

#	ARTICLE	IF	CITATIONS
55	Ion Channel Functions in Early Brain Development. Trends in Neurosciences, 2020, 43, 103-114.	4.2	67
56	Co-occurring medical conditions among individuals with ASD-associated disruptive mutations. Children's Health Care, 2020, 49, 361-384.	0.5	3
57	SCN2A channelopathies in the autism spectrum of neuropsychiatric disorders: a role for pluripotent stem cells?. Molecular Autism, 2020, 11, 23.	2.6	16
58	Drug-drug and drug-food interactions in an infant with early-onset SCN2A epilepsy treated with carbamazepine, phenytoin and a ketogenic diet. British Journal of Clinical Pharmacology, 2021, 87, 1568-1573.	1.1	6
59	Mutations in transmembrane proteins: diseases, evolutionary insights, prediction and comparison with globular proteins. Briefings in Bioinformatics, 2021, 22, .	3.2	17
60	Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update. Acta Neurologica Belgica, 2021, 121, 241-257.	0.5	19
61	Comparative characterization of PCDH19 missense and truncating variants in PCDH19-related epilepsy. Journal of Human Genetics, 2021, 66, 569-578.	1.1	16
62	Developmental and epileptic encephalopathies: what we do and do not know. Brain, 2021, 144, 32-43.	3.7	81
63	Dominant SCN2A mutation with variable phenotype in two generations. Brain and Development, 2021, 43, 166-169.	0.6	4
64	Efficient detection of copy-number variations using exome data: Batch- and sex-based analyses. Human Mutation, 2021, 42, 50-65.	1.1	18
65	Functional genomics of psychiatric disease risk using genome engineering. , 2021, , 711-734.		0
66	Dendritic Integration Dysfunction in Neurodevelopmental Disorders. Developmental Neuroscience, 2021, 43, 201-221.	1.0	14
67	Kv1.1 deficiency alters repetitive and social behaviors in mice and rescues autistic-like behaviors due to <i>Scn2a</i> haploinsufficiency. Brain and Behavior, 2021, 11, e02041.	1.0	9
68	Autism Spectrum Disorder Genetics and the Search for Pathological Mechanisms. American Journal of Psychiatry, 2021, 178, 30-38.	4.0	70
70	Variant in CACNA1G as a Possible Genetic Modifier of Neonatal Epilepsy in an Infant with a De Novo SCN2A Mutation. Journal of Pediatric Genetics, 0, , .	0.3	2
71	Sodium channelopathies in neurodevelopmental disorders. Nature Reviews Neuroscience, 2021, 22, 152-166.	4.9	79
74	SCN2A and Its Related Epileptic Phenotypes. Journal of Pediatric Neurology, 0, , .	0.0	0
75	Computational analysis of 10,860 phenotypic annotations in individuals with SCN2A-related disorders. Genetics in Medicine, 2021, 23, 1263-1272.	1.1	38

#	ARTICLE	IF	CITATIONS
76	Slivers of the spectrum. <i>Nature Biotechnology</i> , 2021, 39, 540-545.	9.4	2
77	A De Novo Missense Variant of SCN2A: Implications and Limitations for Understanding Clinical Phenotype and Treatment Recommendations. <i>Clinical Neuropharmacology</i> , 2021, 44, 138-140.	0.2	0
78	Genetic polymorphisms in SCN2A are not associated with epilepsy risk and AEDs response: evidence from a meta-analysis. <i>Neurological Sciences</i> , 2021, 42, 2705-2711.	0.9	1
79	New paradigms for the treatment of pediatric monogenic epilepsies: Progressing toward precision medicine. <i>Epilepsy and Behavior</i> , 2021, , 107961.	0.9	4
80	Differential Functional Changes of Nav1.2 Channel Causing SCN2A-Related Epilepsy and Status Epilepticus During Slow Sleep. <i>Frontiers in Neurology</i> , 2021, 12, 653517.	1.1	6
82	Biallelic VPS16 variants limit HOPS/CORVET levels and cause a mucopolysaccharidosis-like disease. <i>EMBO Molecular Medicine</i> , 2021, 13, e13376.	3.3	16
83	Elementary mechanisms of calmodulin regulation of NaV1.5 producing divergent arrhythmogenic phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2025085118.	3.3	13
84	Reflections on the genetics-first approach to advancements in molecular genetic and neurobiological research on neurodevelopmental disorders. <i>Journal of Neurodevelopmental Disorders</i> , 2021, 13, 24.	1.5	12
85	Scn2a severe hypomorphic mutation decreases excitatory synaptic input and causes autism-associated behaviors. <i>JCI Insight</i> , 2021, 6, .	2.3	9
86	Inhibition of AKT Signaling Alters $\beta$ IV Spectrin Distribution at the AIS and Increases Neuronal Excitability. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 643860.	1.4	3
88	A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders. <i>European Neuropsychopharmacology</i> , 2021, 48, 49-88.	0.3	29
89	Epilepsy Syndromes in the First Year of Life and Usefulness of Genetic Testing for Precision Therapy. <i>Genes</i> , 2021, 12, 1051.	1.0	36
90	Enhanced slow inactivation contributes to dysfunction of a recurrent <i>SCN2A</i> mutation associated with developmental and epileptic encephalopathy. <i>Journal of Physiology</i> , 2021, 599, 4375-4388.	1.3	9
91	Paradoxical hyperexcitability from NaV1.2 sodium channel loss in neocortical pyramidal cells. <i>Cell Reports</i> , 2021, 36, 109483.	2.9	57
92	Harnessing rare variants in neuropsychiatric and neurodevelopment disorders—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2021, , .	1.8	2
93	Severe deficiency of the voltage-gated sodium channel NaV1.2 elevates neuronal excitability in adult mice. <i>Cell Reports</i> , 2021, 36, 109495.	2.9	43
94	A convergent molecular network underlying autism and congenital heart disease. <i>Cell Systems</i> , 2021, 12, 1094-1107.e6.	2.9	19
95	Developmental dynamics of voltage-gated sodium channel isoform expression in the human and mouse brain. <i>Genome Medicine</i> , 2021, 13, 135.	3.6	19

#	ARTICLE	IF	CITATIONS
96	Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer's patients. <i>Cell Stem Cell</i> , 2021, 28, 1533-1548.e6.	5.2	119
99	Sodium channelopathies of skeletal muscle and brain. <i>Physiological Reviews</i> , 2021, 101, 1633-1689.	13.1	55
100	The Na <sup>v</sup> paradox: reducing sodium currents increases excitability. <i>Trends in Neurosciences</i> , 2021, 44, 767-768.	4.2	2
101	The relationship between pesticide exposure during critical neurodevelopment and autism spectrum disorder: A narrative review. <i>Environmental Research</i> , 2022, 203, 111902.	3.7	20
102	Genetic cause of epilepsy in a Greek cohort of children and young adults with heterogeneous epilepsy syndromes. <i>Epilepsy and Behavior Reports</i> , 2021, 16, 100477.	0.5	4
103	Generation and basic characterization of a gene-trap knockout mouse model of <i>Scn2a</i> with a substantial reduction of voltage-gated sodium channel Na <sub>v</sub> 1.2 expression. <i>Genes, Brain and Behavior</i> , 2021, 20, e12725.	1.1	17
104	Alternative splicing potentiates dysfunction of early-onset epileptic encephalopathy <i>SCN2A</i> variants. <i>Journal of General Physiology</i> , 2020, 152, .	0.9	29
109	The phenotype and treatment of <i>SCN2A</i> -related developmental and epileptic encephalopathy. <i>Epileptic Disorders</i> , 2020, 22, 563-570.	0.7	10
110	Frequently Identified Genetic Developmental and Epileptic Encephalopathy: A Review Focusing on Precision Medicine. <i>Annals of Child Neurology</i> , 2019, 27, 2-12.	0.0	4
111	Neurodevelopmental disorders—the history and future of a diagnostic concept. <i>Dialogues in Clinical Neuroscience</i> , 2020, 22, 65-72.	1.8	162
112	The Role of Ion Channel-Related Genes in Autism Spectrum Disorder: A Study Using Next-Generation Sequencing. <i>Frontiers in Genetics</i> , 2021, 12, 595934.	1.1	4
113	Haploinsufficiency, Dominant Negative, and Gain-of-Function Mechanisms in Epilepsy: Matching Therapeutic Approach to the Pathophysiology. <i>Neurotherapeutics</i> , 2021, 18, 1500-1514.	2.1	9
114	Epigenomic diversity of cortical projection neurons in the mouse brain. <i>Nature</i> , 2021, 598, 167-173.	13.7	47
116	Hyperexcitability and Pharmacological Responsiveness of Cortical Neurons Derived from Human iPSCs Carrying Epilepsy-Associated Sodium Channel Nav1.2-L1342P Genetic Variant. <i>Journal of Neuroscience</i> , 2021, 41, 10194-10208.	1.7	23
119	A recurrent SHANK3 frameshift variant in Autism Spectrum Disorder. <i>Npj Genomic Medicine</i> , 2021, 6, 91.	1.7	9
120	Venom-derived modulators of epilepsy-related ion channels. <i>Biochemical Pharmacology</i> , 2020, 181, 114043.	2.0	11
121	Identification of disease-linked hyperactivating mutations in UBE3A through large-scale functional variant analysis. <i>Nature Communications</i> , 2021, 12, 6809.	5.8	10
122	A matter of space and time: Emerging roles of disease-associated proteins in neural development. <i>Neuron</i> , 2022, 110, 195-208.	3.8	10

#	ARTICLE	IF	CITATIONS
123	It Takes Two to Tango: Channel Interplay Leads to Paradoxical Hyperexcitability in a Loss-of-Function Epilepsy Variant. <i>Epilepsy Currents</i> , 2022, 22, 153575972110579.	0.4	0
124	All our knowledge begins with the antisenses. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	0
125	Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	38
126	Channelopathy of Dravet Syndrome and Potential Neuroprotective Effects of Cannabidiol. <i>Journal of Central Nervous System Disease</i> , 2021, 13, 117957352110480.	0.7	4
127	Gene variant effects across sodium channelopathies predict function and guide precision therapy. <i>Brain</i> , 2022, 145, 4275-4286.	3.7	43
128	Sodium channel expression and transcript variation in the developing brain of human, Rhesus monkey, and mouse. <i>Neurobiology of Disease</i> , 2022, 164, 105622.	2.1	6
129	Disentangling glial diversity in peripheral nerves at single-nuclei resolution. <i>Nature Neuroscience</i> , 2022, 25, 238-251.	7.1	35
130	Structure and Function of Sodium Channel Nav1.3 in Neurological Disorders. <i>Cellular and Molecular Neurobiology</i> , 2023, 43, 575-584.	1.7	2
131	Treatment of Focal-Onset Seizures in Children: Should This Be More Etiology-Driven?. <i>Frontiers in Neurology</i> , 2022, 13, 842276.	1.1	4
132	Amygdala and anterior cingulate transcriptomes from individuals with bipolar disorder reveal downregulated neuroimmune and synaptic pathways. <i>Nature Neuroscience</i> , 2022, 25, 381-389.	7.1	27
134	Further delineation of phenotypic spectrum of <sc><i>SCN2A</i></sc>-related disorder. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 867-877.	0.7	3
135	SCN2A Pathogenic Variants and Epilepsy: Heterogeneous Clinical, Genetic and Diagnostic Features. <i>Brain Sciences</i> , 2022, 12, 18.	1.1	5
136	Commonalities and distinctions between two neurodevelopmental disorder subtypes associated with <sc><i>SCN2A</i></sc> and <sc><i>SCN8A</i></sc> variants and literature review. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2022, 10, e1911.	0.6	5
137	Cellular and behavioral effects of altered NaV1.2 sodium channel ion permeability in <i>Scn2a</i><i>K1422E</i> mice. <i>Human Molecular Genetics</i> , 2022, 31, 2964-2988.	1.4	15
138	<i>SCN2A</i>-related epilepsy of infancy with migrating focal seizures: report of a variant with apparent gain- and loss-of-function effects. <i>Journal of Neurophysiology</i> , 2022, 127, 1388-1397.	0.9	6
141	Hyperexcitability in adult mice with severe deficiency in Na1.2 channels.. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2022, 14, 55-59.	0.8	0
143	Current Ion Channel-targeted Drugs and Potential of Venom-derived Peptides as a Therapeutic New Modality. <i>Venoms and Toxins</i> , 2022, 2, .	0.3	0
144	Paradoxical Hyperexcitability in Disorders of Neurodevelopment. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 826679.	1.4	3



#	ARTICLE	IF	CITATIONS
145	Precision medicine in epilepsy. <i>Progress in Molecular Biology and Translational Science</i> , 2022, , 147-188.	0.9	5
146	Case Report: Phenotype-Driven Diagnosis of Atypical Dravet-Like Syndrome Caused by a Novel Splicing Variant in the SCN2A Gene. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
148	Genetic etiologies of autism: Unpacking pathogenic mechanisms and characteristics. , 2022, , 197-213.		0
149	Zebrafish Modeling of Autism Spectrum Disorders, Current Status and Future Prospective. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	12
150	Voltage-gated sodium channel <i>scn8a</i> is required for innervation and regeneration of amputated adult zebrafish fins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	3
151	Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum. <i>Physiological Reviews</i> , 2023, 103, 433-513.	13.1	38
152	“Virtual patch clamp analysis” for predicting the functional significance of pathogenic variants in sodium channels. <i>Epilepsy Research</i> , 2022, 186, 107002.	0.8	2
153	Calcium and activity-dependent signaling in the developing cerebral cortex. <i>Development (Cambridge)</i> , 2022, 149, .	1.2	11
154	Ion channels and febrile seizures: It’s not just SCN1A. , 2023, , 65-91.		0
155	Identifying novel genetic loci associated with polycystic ovary syndrome based on its shared genetic architecture with type 2 diabetes. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
156	Mechanisms Underlying Circuit Dysfunction in Neurodevelopmental Disorders. <i>Annual Review of Genetics</i> , 2022, 56, 391-422.	3.2	12
157	Quantitative trait locus analysis for endophenotypes reveals genetic substrates of core symptom domains and neurocognitive function in autism spectrum disorder. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	4
159	Delineation of functionally essential protein regions for 242 neurodevelopmental genes. <i>Brain</i> , 2023, 146, 519-533.	3.7	6
160	Measuring the inch stones for progress: Gross motor function in the developmental and epileptic encephalopathies. <i>Epilepsy and Behavior</i> , 2022, 137, 108953.	0.9	3
161	Data-driven historical characterization of epilepsy-associated genes. <i>European Journal of Paediatric Neurology</i> , 2023, 42, 82-87.	0.7	11
162	Autism Spectrum Disorder: Neurodevelopmental Risk Factors, Biological Mechanism, and Precision Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1819.	1.8	24
163	Characterizing Sensory Phenotypes of Subgroups with a Known Genetic Etiology Pertaining to Diagnoses of Autism Spectrum Disorder and Intellectual Disability. <i>Journal of Autism and Developmental Disorders</i> , 0, , .	1.7	5
164	In vivo models to study neurogenesis and associated neurodevelopmental disorders—Microcephaly and autism spectrum disorder. <i>WIREs Mechanisms of Disease</i> , 2023, 15, .	1.5	0

#	ARTICLE	IF	CITATIONS
165	Gene therapy as an emerging treatment for Scn2a mutation-induced autism spectrum disorders. <i>Fundamental Research</i> , 2023, , .	1.6	0
167	Ankyrin-B is lipid-modified by S-palmitoylation to promote dendritic membrane scaffolding of voltage-gated sodium channel NaV1.2 in neurons. <i>Frontiers in Physiology</i> , 0, 14, .	1.3	2
169	Pathogenic <i>SCN2A</i> variants cause early-stage dysfunction in patient-derived neurons. <i>Human Molecular Genetics</i> , 2023, 32, 2192-2204.	1.4	4
170	Functional analysis of a novel de novo <i>SCN2A</i> variant in a patient with seizures refractory to oxcarbazepine. <i>Frontiers in Molecular Neuroscience</i> , 0, 16, .	1.4	1
179	Degeneracy in epilepsy: multiple routes to hyperexcitable brain circuits and their repair. <i>Communications Biology</i> , 2023, 6, .	2.0	10
180	A way forward for diagnosis of patients with extremely rare genetic mutations. <i>Nature Biotechnology</i> , 0, , .	9.4	2
181	Identification of common core ion channel genes in epilepsy and Alzheimer's disease. <i>Irish Journal of Medical Science</i> , 2024, 193, 417-424.	0.8	3
185	A biophysical perspective on the resilience of neuronal excitability across timescales. <i>Nature Reviews Neuroscience</i> , 2023, 24, 640-652.	4.9	5
187	Paroxysmal movement disorders: Paroxysmal dyskinesia and episodic ataxia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 347-365.	1.0	0
188	Neurobiology of Autism Spectrum Disorder. , 2023, , 1-38.		0
193	Molecular testing in autism spectrum disorder. , 2024, , 291-301.		0